Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus (Q37461413)

20 August 2017

1 reference

title

Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus (English)

1 reference

methicillin-resistant Staphylococcus aureus

20 August 2017

0 references

Staphylococcus aureus

1 reference

2

Michael J Rybak

1 reference

20 August 2017

Céline Vidaillac

1

1 reference

PubMed ID

19397461

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

29

1 reference

20 August 2017

5

1 reference

20 August 2017

511-525

1 reference

Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003.

20 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Incidence, antibiotic resistance and clonal relations of MRSA strains isolated from a Romanian university hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Methicillin resistance in Staphylococcus aureus: mechanisms and modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Analysis of cephalosporin antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

PBP 2a mutations producing very-high-level resistance to beta-lactams

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Ceftobiprole: in-vivo profile of a bactericidal cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Pharmacokinetic and pharmacodynamic profile of ceftobiprole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.511

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.5.511

1 reference

20 August 2017

1 reference

PubMed ID

19397461